Publication number: 20230416252
Abstract: The present application generally relates to several processes for the preparation of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one: Compound (I).
Type:
Application
Filed:
October 11, 2021
Publication date:
December 28, 2023
Inventors:
Subha MUKHERJEE, William P. GALLAGHER, Christopher Robert JAMISON, Carolyn S. WEI, Sergei KOLOTUCHIN, Amarjit SINGH, Nicolas CUNIERE, Chris SFOUGGATAKIS, Adrian ORTIZ, Steven R. WISNIEWSKI, Bin ZHENG, Helen Y. LUO, Sébastien François Emmanuel LEMAIRE, Cyril BEN HAÏM, Kostiantyn CHERNICHENKO, Diego Fernando Domenico BROGGINI, Simon Albert WAGSCHAL, Duy Chi Trung CAO, Karl REUTER, Björn SCHMALZBAUER, Philipp KOSCHKER, Martin D. EASTGATE, Dimitri SKLIAR, Alexander ZHDANKO, Christos XIOURAS, Matthew Penfield MOWER, Ngoc Duc TRAN, Ramdane RAHMANI, Xavier Jean-Marie JUSSEAU, Kiran MATCHA, Luca Alessandro PEREGO
Publication number: 20220177482
Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
Type:
Application
Filed:
February 22, 2022
Publication date:
June 9, 2022
Inventors:
Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
Patent number: 11254679
Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
February 22, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C. D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu
Publication number: 20200223852
Abstract: The invention generally relates to an improved process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolodin-1-yl)cyclohexyl)acetamide, as well as novel intermediates employed in the process, which may be useful for the treatment of cancer.
Type:
Application
Filed:
July 19, 2018
Publication date:
July 16, 2020
Inventors:
Burcu Selin Aytar, Alina Borovika, Collin Chan, Joerg Deerberg, Nathan R. Domagalski, Martin D. Eastgate, Yu Fan, Michael David Bengt Fenster, Robert V. Forest, Francisco Gonzalez-Bobes, Rebecca A. Green, Matthew R. Hickey, Nathaniel David Kopp, Thomas E. La Cruz, Kathleen Lauser, Hong Geun Lee, David K. Leahy, Helen Y. Luo, Thomas M. Razler, Scott A. Savage, Chris Sfouggatakis, Maxime C.D. Soumeillant, Serge Zaretsky, Bin Zheng, Ye Zhu